CSNK2A2 Gene

CSNK2A2 Gene

<div class="infobox infobox-gene">
<h3>CSNK2A2</h3>
<table>
<tr><th>Full Name</th><td>Casein Kinase 2 Alpha 2 (Alpha Prime)</td></tr>
<tr><th>Gene Symbol</th><td>CSNK2A2</td></tr>
<tr><th>Chromosome</th><td>16p13.3</td></tr>
<tr><th>NCBI Gene ID</th><td>[1459](https://www.ncbi.nlm.nih.gov/gene/1459)</td></tr>
<tr><th>OMIM</th><td>[115442](https://omim.org/entry/115442)</td></tr>
<tr><th>Ensembl</th><td>[ENSG00000070770](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000070770)</td></tr>
<tr><th>UniProt</th><td>[P19784](https://www.uniprot.org/uniprot/P19784)</td></tr>
<tr><th>Encoded Protein</th><td>[CK2α' protein](/proteins/ck2-alpha-prime-protein)</td></tr>
<tr><th>Associated Diseases</th><td>Parkinson's disease, Oculomotor dysfunction, Cancer</td></tr>
</table>
</div>

Overview

CSNK2A2 Gene

<div class="infobox infobox-gene">
<h3>CSNK2A2</h3>
<table>
<tr><th>Full Name</th><td>Casein Kinase 2 Alpha 2 (Alpha Prime)</td></tr>
<tr><th>Gene Symbol</th><td>CSNK2A2</td></tr>
<tr><th>Chromosome</th><td>16p13.3</td></tr>
<tr><th>NCBI Gene ID</th><td>[1459](https://www.ncbi.nlm.nih.gov/gene/1459)</td></tr>
<tr><th>OMIM</th><td>[115442](https://omim.org/entry/115442)</td></tr>
<tr><th>Ensembl</th><td>[ENSG00000070770](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000070770)</td></tr>
<tr><th>UniProt</th><td>[P19784](https://www.uniprot.org/uniprot/P19784)</td></tr>
<tr><th>Encoded Protein</th><td>[CK2α' protein](/proteins/ck2-alpha-prime-protein)</td></tr>
<tr><th>Associated Diseases</th><td>Parkinson's disease, Oculomotor dysfunction, Cancer</td></tr>
</table>
</div>

Overview

CSNK2A2 (Casein Kinase 2 Alpha 2) encodes the CK2alpha' (alpha prime) catalytic subunit of casein kinase 2 (CK2), a constitutively active serine/threonine kinase.[@stahl2021] While closely related to CSNK2A1 (CK2alpha), the alpha' subunit has distinct expression patterns and substrate preferences, with important roles in cerebellar function, oculomotor control, and neurodegeneration.[@schmitz2005] CSNK2A2 mutations cause a distinctive neurodevelopmental disorder with prominent oculomotor abnormalities.

Gene Structure and Expression

The CSNK2A2 gene spans approximately 10 kb on chromosome 16p13.3 and contains 12 exons.[@yangfeng1994] The encoded 350-amino acid protein:

• High homology: 90% identical to CK2α in the catalytic domain
• Distinct C-terminus: Different from CK2α, contributing to unique substrate specificity
• Tissue-specific expression: More restricted pattern than CSNK2A1

Function

CK2 Holoenzyme Composition

CK2α' can substitute for α in the heterotetrameric holoenzyme:[@litchfield2003]

• α'₂β₂: Homotetramer with two α' catalytic subunits
• αα'β₂: Heterotetramer mixing α and α' subunits
• Substrate differences: Some substrates preferentially phosphorylated by α' vs α

Cerebellar and Vestibular Function

CK2α' plays specific roles in:[@ackermann2016]

Phosphorylation Targets

CK2α' phosphorylates many neuronal substrates:[@meggio2003]

• Synaptic proteins: AMPA receptors, scaffold proteins
• Cytoskeletal elements: Microtubule-associated proteins
• Signaling molecules: Transcription factors, kinases
• Ion channels: Modulates neuronal excitability

Disease Associations

CSNK2A2-Related Neurodevelopmental Disorder

Biallelic and heterozygous CSNK2A2 variants cause:[@chao2020]

• Oculomotor dysfunction: Nystagmus, strabismus, impaired smooth pursuit
• Cerebellar signs: Ataxia, dysmetria, intention tremor
• Developmental delay: Motor milestones, speech delay
• Intellectual disability: Mild to moderate
• Behavioral features: Autism spectrum, ADHD

Parkinson's Disease

CK2α' contributes to PD pathology:[@inglis2009]

• [α-synuclein](/proteins/alpha-synuclein) phosphorylation: Ser129 phosphorylation
• Dopaminergic vulnerability: CK2 inhibition protects [neurons](/entities/neurons)
• Mitochondrial function: CK2 regulates mitophagy proteins

Cancer

Like CSNK2A1, α' is implicated in oncogenesis:[@trembley2010]

• Overexpression: In certain tumors
• Pro-survival signaling: AKT pathway activation
• Therapeutic target: CK2 inhibitors affect both α and α'

Expression Profile

| Tissue | Expression Level | Notes |
|--------|------------------|-------|
| Cerebellum | Very high | Purkinje cells, motor control |
| Brainstem | High | Oculomotor nuclei |
| Vestibular system | High | Balance, spatial orientation |
| Cerebral cortex | Moderate | Lower than CK2α |
| Hippocampus | Moderate | Memory circuits |

Common Variants

| Variant | dbSNP | Effect | Clinical Relevance |
|---------|-------|--------|-------------------|
| rs2072555 | NCBI | Intronic | Parkinson's disease association |
| rs3731320 | NCBI | 5' UTR | Gene expression modifier |
| rs7186521 | NCBI | Intronic | Cancer risk modifier |

Therapeutic Implications

CK2 Inhibition

CK2α' as a therapeutic target:[@chon2022]

Challenges

• Essential function: Complete CK2 inhibition is toxic
• Partial inhibition: Therapeutic window may be narrow
• [Blood-brain barrier](/entities/blood-brain-barrier): Need CNS-penetrant compounds
• Distinguishing α vs α' effects: Difficult to parse contributions

See Also

• [CSNK2A1 Gene](/genes/csnk2a1)
• [CSNK2B Gene](/genes/csnk2b)
• [Cerebellum](/brain-regions/cerebellum)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Vestibular System](/brain-regions/vestibular-system)

External Links

• [GeneCards: CSNK2A2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CSNK2A2)
• [UniProt: P19784](https://www.uniprot.org/uniprot/P19784)
• [NCBI Gene: 1459](https://www.ncbi.nlm.nih.gov/gene/1459)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving CSNK2A2 Gene discovered through SciDEX knowledge graph analysis: